Ion-binding and pharmacological properties of Tyr6 and Tyr9 antamanide analogs.
In order to investigate the antiproliferative properties of antamanide, we have synthesized and studied two antamanide analogs where the phenylalanine residue in positions 6 or 9 is substituted by tyrosine, their corresponding linear forms and the cyclic and linear des Phe5,Phe6-Tyr9-analogs. Antamanide and its biologically active synthetic analogs are able to form highly stable complexes with metal ions, particularly Na+, K+ and Ca2+. We studied the ion-binding properties of the Tyr-antamanide analogs by CD and Tb3+ -mediated fluorescence in acetonitrile. In this medium the far-and near-UV CD spectra of the neat Tyr6-antamanide analog are very similar to that of the parent cyclic decapeptide. Substantial differences occur on the contrary in the CD spectra of the neat Tyr9-antamanide, particularly in the regions at 220 nm and 270-290 nm. In acetonitrile, as already found for antamanide, the interaction with the above-mentioned metal ions always produces evident changes in the far- and near-UV CD spectra of both analogs. On the contrary, the CD spectra of the linear deca- and octa- and of the cyclic octa-analogs are affected by the presence of metal ions only in the near-UV region. In the same solvent the Tb3+ -mediated fluorescence spectra of all the synthetic peptides are remarkably affected by the addition of ions. On the basis of the spectral total changes, by using either or both the spectroscopic techniques, it has been possible to determine the ion binding constants for all the linear and cyclic Tyr-antamanide analogs and to compare them with that of the parent peptide. The antitoxic and antiproliferative activities of these antamanide analogs have been tentatively correlated to their ion-binding properties. A preliminary account of this work was given in (1).
CNR, Biopolymer Research Center, Department of Organic Chemistry, University of Padua, Italy.
P
P
Ruzza
A
A
Calderan
B
B
Biondi
M
M
Carrara
T
T
Tancredi
G
G
Borin
D000097:Acetonitriles / Q000737:chemistry; D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000818:Animals; D000931:Antidotes / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D002412:Cations / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002942:Circular Dichroism; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008670:Metals / Q000378:metabolism*; D008674:Metals, Rare Earth / Q000378:metabolism; D051379:Mice; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D010590:Phalloidine / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D013725:Terbium / Q000378:metabolism; D014407:Tumor Cells, Cultured
D000097:Acetonitriles; D000931:Antidotes; D002412:Cations; D008670:Metals; D008674:Metals, Rare Earth; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D013725:Terbium; C100265:antamanide; D010590:Phalloidine; D012964:Sodium; D011188:Potassium; D002118:Calcium; C032159:acetonitrile